GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AbCellera Biologics Inc (STU:8QQ) » Definitions » ROC (Joel Greenblatt) %

AbCellera Biologics (STU:8QQ) ROC (Joel Greenblatt) % : -69.66% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is AbCellera Biologics ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. AbCellera Biologics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -69.66%.

The historical rank and industry rank for AbCellera Biologics's ROC (Joel Greenblatt) % or its related term are showing as below:

STU:8QQ' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -88.35   Med: 60.27   Max: 230.97
Current: -78.15

During the past 6 years, AbCellera Biologics's highest ROC (Joel Greenblatt) % was 230.97%. The lowest was -88.35%. And the median was 60.27%.

STU:8QQ's ROC (Joel Greenblatt) % is ranked better than
68.79% of 1461 companies
in the Biotechnology industry
Industry Median: -318.48 vs STU:8QQ: -78.15

AbCellera Biologics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


AbCellera Biologics ROC (Joel Greenblatt) % Historical Data

The historical data trend for AbCellera Biologics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbCellera Biologics ROC (Joel Greenblatt) % Chart

AbCellera Biologics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -27.31 229.67 142.50 115.64 -87.24

AbCellera Biologics Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -108.66 -75.56 -78.15 -87.82 -69.66

Competitive Comparison of AbCellera Biologics's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, AbCellera Biologics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AbCellera Biologics's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AbCellera Biologics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where AbCellera Biologics's ROC (Joel Greenblatt) % falls into.



AbCellera Biologics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(28.051 + 1.015 + 42.101) - (79.582 + 23.906 + 1.4210854715202E-14)
=-32.321

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(31.665 + 0.679 + 42.699) - (74.69 + 16.714 + -0.00099999999999056)
=-16.36

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of AbCellera Biologics for the quarter that ended in Mar. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-189.956/( ( (263.817 + max(-32.321, 0)) + (281.595 + max(-16.36, 0)) )/ 2 )
=-189.956/( ( 263.817 + 281.595 )/ 2 )
=-189.956/272.706
=-69.66 %

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AbCellera Biologics  (STU:8QQ) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


AbCellera Biologics ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of AbCellera Biologics's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


AbCellera Biologics (STU:8QQ) Business Description

Traded in Other Exchanges
Address
2215 Yukon Street, Vancouver, BC, CAN, V5Y 0A1
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the most effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and leading pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

AbCellera Biologics (STU:8QQ) Headlines

No Headlines